Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's Disease (HD) is a severe neurodegenerative disorder characterized by movement, cognitive, and psychiatric symptoms.
• HD is caused by an autosomal dominant trinucleotide repeat expansion mutation.
• Currently, no cure exists for HD, but treatments can alleviate symptoms.

Purpose of the Study:

• To identify and summarize drugs in phase III clinical trials for Huntington's Disease (HD).
• To provide a resource on current interventional therapies for HD in the United States.

Main Methods:

• Systematic review of ClinicalTrials.gov for phase III interventional HD trials.
• Inclusion criteria: recruiting, active not recruiting, or completed studies with updates in the past year.
• PubMed was used for supplementary information on identified trials.

Main Results:

• Nine clinical trials met the search criteria.
• Eight trials focused on specific drugs: metformin, dextromethorphan/quinidine, deutetrabenazine, valbenazine, Cellavita HD, pridopidine, SAGE-718, and RO7234292 (RG6042).
• Four of the investigated drug treatments are already FDA-approved.

Conclusions:

• This review consolidates information on promising HD therapies currently in late-stage clinical development.
• Highlights the availability of FDA-approved treatments among those in phase III trials.
• Offers a valuable resource for understanding the current landscape of Huntington's Disease therapeutic interventions.